These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Grover ND; Limaye RP; Gokhale DV; Patil TR Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aboulatta L; Haidar L; Abou-Setta A; Askin N; Rabbani R; Lavu A; Peymani P; Zarychanski R; Eltonsy S CNS Drugs; 2023 Nov; 37(11):941-956. PubMed ID: 37973769 [TBL] [Abstract][Full Text] [Related]
7. Zonisamide in managing impulse control disorders in Parkinson's disease. Bermejo PE; Ruiz-Huete C; Anciones B J Neurol; 2010 Oct; 257(10):1682-5. PubMed ID: 20509031 [TBL] [Abstract][Full Text] [Related]
8. Zonisamide: a new drug for Parkinson's disease. Murata M Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722 [TBL] [Abstract][Full Text] [Related]
9. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study. Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449 [TBL] [Abstract][Full Text] [Related]
10. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]
11. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. Tsuboi Y; Nakamura M; Maruyama H; Matsumoto Y J Neurol Sci; 2021 Nov; 430():120026. PubMed ID: 34715471 [TBL] [Abstract][Full Text] [Related]
12. Zonisamide: review of its use in epilepsy therapy. Zareba G Drugs Today (Barc); 2005 Sep; 41(9):589-97. PubMed ID: 16341290 [TBL] [Abstract][Full Text] [Related]
13. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
14. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C; Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606 [TBL] [Abstract][Full Text] [Related]
16. Zonisamide for the treatment of Parkinson's disease. Miwa H Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. Pinter MM; Pogarell O; Oertel WH J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413 [TBL] [Abstract][Full Text] [Related]
18. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Brodie MJ; Ben-Menachem E; Chouette I; Giorgi L Acta Neurol Scand Suppl; 2012; (194):19-28. PubMed ID: 23106522 [TBL] [Abstract][Full Text] [Related]